<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="402">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01997944</url>
  </required_header>
  <id_info>
    <org_study_id>921302</org_study_id>
    <nct_id>NCT01997944</nct_id>
  </id_info>
  <brief_title>Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients</brief_title>
  <official_title>Phase Ib Study of Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein in Chronic Hepatitis B Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Bio-Fortune Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Bio-Fortune Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study that will be conducted at a single site in China to evaluate the
      safety,tolerability and PK/PD profile of multiple dose of recombinant human serum
      albumin/interferon alpha2a fusion protein in chronic hepatitis B patients.The total duration
      of study participation is up to 22 weeks for each subject,including 4 weeks screening
      period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease of HBV DNA</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCss</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css_av</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css_min</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css-max</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>18 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Human Serum Albumin/interferon alpha2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Serum Albumin/interferon alpha2a 600,750 or 900 mcg multiple dose S.C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegasys</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peginteferon 180 mcg multiple dose S.C.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Serum ALbumin/interferon alpha2a</intervention_name>
    <description>600,750 or 900 mcg dosing every 2 weeks</description>
    <arm_group_label>Human Serum Albumin/interferon alpha2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>180 mcg dosing every week</description>
    <arm_group_label>Pegasys</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-75 years

          -  Chronic HBV infection (serum HBsAg detectable for &gt; 6 months)

          -  Serum HBeAg positive with HBV DNA &gt;10^6copies/mL (or &gt;20,000 IU/mL),orSerum HBeAg
             negative with HBV DNA &gt;10^5copies/mL (or &gt;2,000 IU/mL)

          -  Serum ALT must be &gt; 2 x ULN but below 10 x ULN

        Exclusion Criteria:

          -  Steroid treatment or immunosuppression 3 months prior to entry.

          -  Interferon therapy or nucleotides analogues therapy in 6 months prior to entry.

          -  Active lung disease or history of interstitial lung disease.

          -  Hb&lt; LLN or, and ANC &lt; 750/mm3 or , and platelet count &lt; 75,000 mm3 ,or WBC&lt;3000/mm3 .

          -  Significant chronic medical conditions other than chronic hepatitis B which in the
             opinion of the investigator preclude enrollment into the study.

          -  Evidence of hepatic decompensation (i.e., Child-Pugh score of B or C).

          -  Seropositive for HIV, HCV, or HDV (Hepatitis Delta virus).

          -  History of thyroid disease or current treatment for thyroid disease.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junqi Niu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jilin University First Affiliated Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jilin University First Affiliated Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 14, 2014</lastchanged_date>
  <firstreceived_date>November 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albunex</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
